Expression of HE4 in Endometrial Cancer and Its Clinical Significance

Table 2

HE4 expression in endometrial cancer with different clinical parameters.

Features		Cases	Positive cases	Positive; rate (%)	Strong positive; cases	Strong; positive; rate (%)
EC type	I	28	23	82.14	15	53.57	0.456	0.747
	II	74	65	87.84	37	50.00
Pathological type	Endometrial adenocarcinoma	49	45	91.84	26	53.06
	Uterine papillary serous carcinoma	21	15	71.43	8	38.10
	Clear cell carcinoma	22	19	86.36	11	50.00
	Mucous carcinoma	4	4	100.00	3	75.00
	Undifferentiated carcinoma	3	2	66.67	2	66.67
	Squamous cell carcinoma	2	2	100.00	1	50.00
	Small cell carcinoma	1	1	100.00	1	100.00
FIGO stage	Ia; Ib; II; III; IV	38; 23; 7; 28; 6	29; 21; 5; 27; 6	76.32; 91.30; 71.43; 96.43; 100	12; 13; 2; 20; 5	31.57; 56.52; 28.57; 71.42; 83.33	Others	7; Others
Differentiation; level	High	22	16	72.72	9	34.62	Others
	Middle	28	24	85.71	13	46.43
	Low	52	48	92.31	30	57.69
Lymphatic metastasis	No	59	48	81.36	22	59.46
	Yes	27	26	96.30	21	77.78
	No lymph node cleaning	16	14	87.50	9	56.25

Note: of HE4 positive rate in each group; of strongly positive HE4 expression rate in each group.